[The fine line between innovation and risk : Is anti-NGF a pain medication of the future?].
H-G
HG
Schaible
D000700:Analgesics / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D017326:Clinical Trials, Phase III as Topic; D004059:Diffusion of Innovation; D018450:Disease Progression; D064420:Drug-Related Side Effects and Adverse Reactions; D057239:Early Termination of Clinical Trials; D006801:Humans; D006930:Hyperalgesia / Q000235:genetics / Q000503:physiopathology; D020932:Nerve Growth Factor / Q000037:antagonists & inhibitors* / Q000502:physiology; D009619:Nociceptors / Q000187:drug effects; D010003:Osteoarthritis / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D012333:RNA, Messenger / Q000235:genetics; D020917:Receptor, trkA / Q000235:genetics; D012307:Risk Factors; D015854:Up-Regulation / Q000235:genetics
D000700:Analgesics; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C502240:NGF protein, human; D012333:RNA, Messenger; D020932:Nerve Growth Factor; D020917:Receptor, trkA; C549319:tanezumab